A phase II study of interferon-α, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation

British Journal of Urology

Volumn 77, Issue 5, 1996, Pages 638-649

  Joffe, J K ^a,b   Banks, R E ^a   Forbes, M A ^a   Hallam, S ^a   Jenkins, A ^a   Patel, P M ^c   Hall, G D ^a   Velikova, G ^a   Adams, J ^a   Crossley, A ^a   Johnson, P W M ^a   Whicher, J T ^a   Selby, P J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b St James's University Hospital ^*  (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

5 Fluorouracil; Complement; Elastase; Interferon ; Interleukin 2; Kallikrein; Protease; Renal cancer; Therapy; Toxicity

Indexed keywords

ALPHA 1 ANTITRYPSIN; COMPLEMENT COMPONENT C3A; ELASTASE; FLUOROURACIL; PREKALLIKREIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ALPHA 1-ANTITRYPSIN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMPLEMENT C3A; FEMALE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; PANCREATIC ELASTASE; PREKALLIKREIN; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0030420513     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Marris DT. Hormonal therapy and chemotherapy ol renal carcinoma. Sem Oncol 198 i; 10: 422-30
2. Yagoda A, Petrylak D. Thompson S. Cytoloxic chemotherapy l'or advanced renal cell carcinoma (Review). Urol Clin North Am 1993: 20: 305-21
3. Piltman K. Selby P. The management of renal cell carcinoma, frit Rev Oncol/Heiuatol 1994: 16: 181-200
4. W'hittington R. Faulds D. lnlerleukin-2: A review of ils pharmacological properties and therapeutic use in patients with cancer. Dnit/s 1993: 46: 446-514
5. Jones M. Philip T, Palmer P et al. The impact ot'inlerleukin-2 on survival in renal cancer: a multivariate analysis. Cancer mother 1993: 8: 275-88
6. Rosenberg SA, Yang JC, Topalian SI. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994: 271: 907-1 3
7. Fossa S. Jones M, Johnson P et ni. Intert'eron-alpha and survival in renal cell cancer. Br} Uivl 1995: 76: 286-290
8. Thiounn N. Mathiot C. Dorval T et al. Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-α in the treatment of metastatic renal cell carcinoma. Br J U ml 1995: 75: 586-9
9. Janssen RAJ. Mulder NH, The TU. de Lei) L. The immunobiological effects of interleukin-2 in vivo. Cancer Inimwttil Inimunother 1994; 59: 207-16
10. De Boer JP. Wolbink G-J. Thijs I.Ci. Haars JW. Wagstäff J. Hack CF. Interplay of complement and cytokines in the pathogenesis of septic shock, Innniuiopharmacol 1992: 24: 135-48
11. Baars JW. Hack CE, Wagstaff J et al. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. Kr J Cancer 1992: 65: 96-101
12. Fleischmann JD. Shingleton WB. Gallagher C. Ratnoff 01). Chahine A. Fibrinolysis. thrombocytopenia and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. J Lab Clin Med 1991: 117: 76-82
13. Hack CE. Wagstaff J. Strack Van Schijndel RJM et al. Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock, Thromb Haemostasia 1991; 65: 497-503
14. Vachino G, Gelfand JA. Atkins MB. Tamerius JD. Demchak P. Mier JW. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): Binding of complement and C-reactive protein by IL-2-activated lymphocytes. Mood 1991: 78: 2505-1 3
15. Moore FD. Schoof DD. Rodriek M, Hberlein TJ. The systemic complement activation caused by interleukin-2/ lymphokine-aetivated killer-cell therapy of cancer causes minimal systemic neutrophil activation, lut J Cancer 1991; 49: 504-8
16. Thijs LG. Hack CE. Strack Van Schijndel RJM et al. Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side-effects. J Immimol 1990: 144: 2419-24
17. Rabinovici R. Sofronski MD. Borboroglu P et al Interleukin-2-induced lung injury: The role of complement, Curr Res 1994: 74: 329-35
18. Ogilvie AC. Baars JW. Herenberg AJM el ul. A pilot study to evaluate the effects of Cl esterase inhibitor on the toxidty of high-dose interleukin 2. Kr J Cancer 1994: 69: 596-8
19. Atzpodien J. Korl'er A. Franks CR. Polivvoda H. Kirchner H. Home therapy with recombinant interIeukin-2 and interI'eron- -2b in advanced human malignancies. Laufet 1990: 335: 1509-12
20. Atzpodien J. Kirchner H. Lopez Hänninen H, Decken M. Fenner M, Poliwoda H. lnlerleukin-2 in combination with inlerferon-oe and 5-lluorouracü for metastalic renal cell cancer. Eur J Cancer [AJ 1993: 29A Suppl. 5: S6-8
21. de Haes JC. van Knippenherg FC. Neijt JP. Measuring psychological and physical distress in cancer patienls: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 1990: 62: 1034-8
22. Zigmond A. Snaith RP. The hospital anxiety and depression scale. Ada Psnchiatr Scand 1983: 67: 361-70
23. Walkins J. Wild G. Smith S. Nafamostat to stabilise plasma samples taken for complement measurements. Lancet 1989: April 22nd: 896-7
24. 1 antitrypsin) in patients with rheumatoid arthritis: interference by rheumatoid factor. Ann Rheum Dis 1990; 49: 18-21
25. De La Cadena RA. Scott CF. Colman RW. Evaluation of a microassay for human plasma prekallikrein. J Lab Clin Med 1987: 109: 601-7
26. Kish JA. Wolf M, Crawlbrd ED et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study Cimcer 1994; 74: 916-9
27. Murphy BR, Rynard SM, Einhorn I,H, Loehrer PJ. A phase II trial of Interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study. Invest New Driiys 1992: 10: 225-30
28. Haarstad H. jacobsen AB. Schjolseth SA. Risberg T. Fossa SD. Interferon-alpha. 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. Ann Oncol 1994; 5: 245-8
29. Zaniboni A, Simoncini E, Marpicati P. Montini E, Ferrari V, Marini G. Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer. J Chemother 1989; 1: 350-1
30. Sella A. Kilbourn RG. Gray I et al. Phase I study of interleukin-2 combined with interferon-alpha and 5-lluorouracil in patients with metastatic renal cell cancer. Cancer Mother 1994; 9: 103-1 1
31. Sella A. Logothetis CJ. Fitz K et al. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in melastatic renal cell cancer. J Urol 1992: 147: 573-7
32. Huland E. Heinzer H. Huland H. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and Interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment. J Cancer Res Clin Oncol 1994; 120: 221-8
33. J.K. Jolle. MD MRCP. Senior Clinical Scientist. R.H. Hanks. BSc MSc PhD. Lecturer. .VI.A. Forties. BSc MPhil. Senior Technician. S. Hallam, RdN. Senior Research Sister. A. [enkins, RG\. Research Sister. P.M. Patel PhD MRCP. Clinician Scientist. G.D. Hall. MRCP. Research Fellow. G. Velikova. Specialist -Internal Medicine (BulgariaI. Visiting Senior Registrar. J. Adams. MRCP. Registrar. A. Crossley. BPharm MRPharmS. Senior Pharmacist. P.W.M. Johnson. Ml) MRCP. Senior Lecturer. J.T. YVhicher. MA MSc MB. BChir FRCPath. Professor. P.J. Seibv. MA MD FRCP FRCR. Professor. Correspondence: Dr J.K. Joffe, ICRF Cancer Medicine Research Unit. St James's university Hospital. Beckelt Street. Leeds LS9 7TF, UK